Modificare „Dynavax Technologies Corporation”

Pagina dedicata companiei Dynavax Technologies Corporation listata cu simbolul US.DVAX

==Descriere companie==
Dynavax Technologies Corporation (www.dynavax.com) is a commercial-stage biopharmaceutical company that is focused on developing and commercializing vaccines. The Company's products include HEPLISAV-B and CpG 1018. The HEPLISAV-B is indicated for the prevention of infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. HEPLISAV-B is a two-dose hepatitis B vaccine for adults. HEPLISAV-B is a sterile solution for injection presented in 0.5 mL single-dose prefilled syringes. The Company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. The Company is also engaged in developing CpG 1018 as a vaccine adjuvant through research collaborations and partnerships. HEPLISAV-B combines 1018, a toll-like receptor (TLR9) agonist adjuvant, and recombinant hepatitis B surface antigen (rHBsAg). It is primarily focused on adjuvanted vaccines for coronavirus disease (COVID-19), pertussis, and universal influenza.

==Grafic actiuni companie==
<iframe key="tradeville" path="graficSimbol/US.DVAX" />

==Ultimele stiri despre Dynavax Technologies Corporation (US.DVAX)==
<dynamicpagelist>
category=US.DVAX
count=10
order=descending
addfirstcategorydate=false
</dynamicpagelist>

[[Categorie:US.DVAX]][[Categorie:Stiri despre companii]]